| | Call Details | Novacea Earnings Conference Call (Q1 2008) Mon,
May 12, 2008, 4:30 pm Eastern
| | About Novacea
(NasdaqGM:NOVC) |
| | Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The companys product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California. |
| More
Info:
Quote
|
Profile
|
Reports
|
Research
|
Msgs
|
Insider
|
Financials
|
Analyst Ratings |
|